PRESS RELEASES

Year
January 09 | 2025
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06 | 2025
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
December 23 | 2024
RAPT Therapeutics Announces $150 Million Private Placement
December 23 | 2024
RAPT Therapeutics Announces $150 Million Private Placement
December 23 | 2024
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
November 12 | 2024
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 11 | 2024
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
August 08 | 2024
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
May 09 | 2024
RAPT Therapeutics Reports First Quarter 2024 Financial Results
April 09 | 2024
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients